NDC properties for "2500 MG Androgel 0.01 MG/MG Topical Gel" (RxCUI 1597124)
About this data
The tables show NDC propoerties for 2500 MG Androgel 0.01 MG/MG Topical Gel with the RxCUI 1597124
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product
Details for 2500 MG Androgel 0.01 MG/MG Topical Gel (RxCUI 1597124)
| MMSL_CODE | BD22846 |
|---|---|
| NDA | NDA021015 |
| RxCUI | 1597124 |
| SPL_SET_ID | d466910c-9a76-44e8-8759-4717ec2c591f |
| VUID | 4029618 |
| Prescribable Synonym | AndroGel 1 % (25MG / 2.5GM) Transdermal Gel |
| RXNAV_STR | Androgel 1 % Transdermal Gel, 2.5 GM |
| RxNorm Name | 2500 MG testosterone 0.01 MG/MG Topical Gel [Androgel] |
| RxNorm Synonym | 2500 MG Androgel 0.01 MG/MG Topical Gel |
| RxNorm Synonym | Androgel 1 % Transdermal Gel, 2.5 GM |
| Related queries | Interactions (for RxCUI 1597124) |
NDC Properties
NDC Item 00051842501
| NDC 9 | 0051-8425 |
|---|---|
| NDC 10 | 0051-8425-01 |
| NDC Item | 00051842501 |
| Packaging | 2.5 g in 1 PACKET |
| DCSA | CIII |
| FDA SPL set id | 616838 |
| Labeler | AbbVie Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time high | 2022-10-31 |
| Marketing effective time low | 2011-03-14 |
| Marketing status | COMPLETED |
| NDA | NDA021015 |
| Related queries | Properties for NDC 9 0051-8425 |
NDC Item 00051842530
| NDC 9 | 0051-8425 |
|---|---|
| NDC 10 | 0051-8425-30 |
| NDC Item | 00051842530 |
| Packaging | 30 PACKET in 1 CARTON (0051-8425-30) / 2.5 g in 1 PACKET (0051-8425-01) |
| DCSA | CIII |
| FDA SPL set id | 616838 |
| Labeler | AbbVie Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time high | 2022-10-31 |
| Marketing effective time low | 2011-03-14 |
| Marketing status | COMPLETED |
| NDA | NDA021015 |
| Related queries | Properties for NDC 9 0051-8425 |
NDC Item 00051842501
| NDC 9 | 0051-8425 |
|---|---|
| NDC 10 | 0051-8425-01 |
| NDC Item | 00051842501 |
| Packaging | 2.5 g in 1 PACKET |
| DCSA | CIII |
| FDA SPL set id | 616838 |
| Labeler | AbbVie Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time high | 2022-10-31 |
| Marketing effective time low | 2011-03-14 |
| Marketing status | COMPLETED |
| NDA | NDA021015 |
| Related queries | Properties for NDC 9 0051-8425 |
NDC Item 00051842530
| NDC 9 | 0051-8425 |
|---|---|
| NDC 10 | 0051-8425-30 |
| NDC Item | 00051842530 |
| Packaging | 30 PACKET in 1 CARTON (0051-8425-30) / 2.5 g in 1 PACKET (0051-8425-01) |
| DCSA | CIII |
| FDA SPL set id | 616838 |
| Labeler | AbbVie Inc. |
| Label type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Marketing effective time high | 2022-10-31 |
| Marketing effective time low | 2011-03-14 |
| Marketing status | COMPLETED |
| NDA | NDA021015 |
| Related queries | Properties for NDC 9 0051-8425 |